Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 94 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2017, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline landscape.

Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor executive functioning, inability to sustain attention and problems with working memory. Predisposing factors include family history, age and autoimmune diseases. Treatment includes antipsychotic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 10, 16 and 2 respectively.

Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development
AbbVie Inc
Amarantus Bioscience Holdings Inc
Astellas Pharma Inc
AstraZeneca Plc
Bristol-Myers Squibb Company
Coronis NeuroSciences Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
H. Lundbeck A/S
Intra-Cellular Therapies Inc
Iproteos SL
Luc Therapeutics Inc
Neuralstem Inc
Pfizer Inc
Sage Therapeutics Inc
Saniona AB
SK Biopharmaceuticals Co Ltd
Spherium Biomed SL
Sunovion Pharmaceuticals Inc
Takeda Pharmaceutical Company Ltd
Vanda Pharmaceuticals Inc
Cognitive Impairment Associated With Schizophrenia (CIAS) - Drug Profiles
A-431404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AN-761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQW-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-4345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-5736 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-3288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basmisanil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-955829 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
davunetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-3748 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eltoprazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erteberel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IC-041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPR-19 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITI-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSN-2814617 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LUAF-64280 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSI-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-03463275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04958242 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roflumilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGE-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKLA-4R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-14040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-058 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-831 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products
Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones
Featured News & Press Releases
Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a "RETOS-Colaboracion" grant
Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia
Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Company, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies Inc, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos SL, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Luc Therapeutics Inc, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neuralstem Inc, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sage Therapeutics Inc, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H1 2017